<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02223884</url>
  </required_header>
  <id_info>
    <org_study_id>4-2011-0300</org_study_id>
    <nct_id>NCT02223884</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the phase II, single-arm, single-center study assessing the efficacy of weekly
      docetaxel plus carboplatin in second-line treatment of malignant melanoma (unresectable or
      metastatic) who has failed dacarbazine or temozolomide contained therapy. The primary end
      point is overall response rate according to RECIST 1.1 criteria assessed using CT or MRI and
      secondary end point includes disease control rate, progression free survival, overall
      survival and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>every 6 weeks, up to 4 year</time_frame>
    <description>Response rate evaluation based on RECIST 1.1 confirmed by CT or MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>every 6 weeks, up to 4 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>every 6 weeks, up to 4 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>every 6 weeks, up to 4 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>every 6 weeks, up to 4 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>weekly docetaxel and carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel 35mg/m2</intervention_name>
    <description>D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks</description>
    <arm_group_label>weekly docetaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC3</intervention_name>
    <description>D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks</description>
    <arm_group_label>weekly docetaxel and carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven malignant melanoma (recurred or metastatic) that
             had progressed during or after receiving at least one cycle of a regimen containing
             dacarbazine or temozolomide in the advanced setting

          -  Measurable disease (RECIST)

          -  ECOG performance 0-2

          -  Adequate organ function

          -  Total bilirubin &lt;1.5N ; ASAT and ALAT &lt;2.5N

          -  Serum Creatinin &lt; 1.5N

          -  ANC ≥ 1,500/mm³ (G-CSF allowed)

          -  Platelets ≥ 100,000/mm³

          -  Hb ≥ 9.0 g/dL

          -  Life expectancy of at least 12 weeks

          -  Signed Written Informed Consent

        Exclusion Criteria:

          -  Symptomatic brain metastasis

          -  Previous history of treatment with taxane or platinum agent containing chemotherapy

          -  Previous major surgery within 2 weeks before the start of the trial, or a failure to
             recover from the surgery

          -  Previous history of other malignancies within 5 years except for cured skin basal cell
             carcinoma or cured in-situ cervix cancer

          -  Other severe medical conditions (infection, uncontrolled hypertension, heart failure,
             MI history within 6 months)

          -  Sensitivity to platinum agents or docetaxel

          -  Uncontrolled seizure

          -  Women pregnant or nursing

          -  Alcohol or drug abuser
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <last_update_submitted>August 27, 2014</last_update_submitted>
  <last_update_submitted_qc>August 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant melanoma, second-line treatment, docetaxel, carboplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

